利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

66 records (took 0.012 seconds)

    MICROPLATE
    1.
    发明申请
    MICROPLATE 审中-公开
    微板

    公开(公告)号：WO2011030018A3

    公开(公告)日：2011-12-29

    申请号：PCT/FR2010000615

    申请日：2010-09-10

    Applicant: PF MEDICAMENT ,  SAMSON ARNAUD

    Inventor： SAMSON ARNAUD

    IPC: C12M1/18 ,  B01L3/00

    CPC classification number: C12M23/12 ,  B01L3/5085 ,  B01L2300/0829 ,  Y10T29/49

    Abstract: The subject of the present invention is a microplate, or microtitration plate, having an invagination consisting of a continuous peripheral channel making it possible to add thereto, in a single delivery step, a liquid acting as "evaporation curtain". The invention also relates to a device comprising such a microplate, to a manufacturing process and to the use of such a microplate.

    Abstract translation: 本发明的主题是微孔板或微量滴定板，其具有由连续的外围通道构成的内陷，使得可以在单个输送步骤中将作为“蒸发幕”的液体添加到其中。 本发明还涉及一种包括这种微孔板的装置，涉及制造工艺和使用这种微板。

    METHOD FOR IMPREGNATION WITH SUPERCRITICAL CO2
    2.
    发明申请
    METHOD FOR IMPREGNATION WITH SUPERCRITICAL CO2 审中-公开
    用超临界二氧化碳去除的方法

    公开(公告)号：WO2010130799A3

    公开(公告)日：2011-05-19

    申请号：PCT/EP2010056582

    申请日：2010-05-12

    Applicant: PF MEDICAMENT ,  LOCHARD HUBERT ,  FREISS BERNARD

    Inventor： LOCHARD HUBERT ,  FREISS BERNARD

    IPC: A61K9/18 ,  A61K31/165 ,  A61K31/192 ,  A61K31/216 ,  A61K31/475 ,  A61P13/10 ,  A61P21/04 ,  A61P25/18 ,  A61P29/00

    CPC classification number: A61K9/1694 ,  A61K9/1635 ,  A61K9/1652

    Abstract: The present invention relates to a batch method for impregnating a nonporous polymer pharmaceutical carrier with an active substance, characterised in that said method includes the following consecutive steps: a) mixing the active substance and the nonporous polymer pharmaceutical carrier, the pharmaceutical carrier being in a solid form and insoluble in supercritical CO2 and not being non-crosslinked polyvinylpyrrolidone; b) performing a step of molecular diffusion in the absence of water by contacting, in a static mode without agitation, the mixture obtained in step a) with supercritical CO2 at a pressure of 80 to 170 bars, at a temperature of 31 to 90°C for 1 to 6 hours; c) recovering the polymer pharmaceutical carrier impregnated with the active substance obtained in step b), the impregnated pharmaceutical carrier being nonporous and being in a solid form and the active substance being in an amorphous form, the method being implemented in the absence of an additional solvent. The invention further relates to a polymer pharmaceutical carrier in a nonporous solid form impregnated with an active substance characterised in that said carrier can be obtained by the method according to the present invention, in that the active substance is in an amorphous form and is water-soluble, and in that the polymer pharmaceutical carrier is not non-crosslinked polyvinylpyrrolidone and is insoluble in supercritical CO2.

    Abstract translation: 本发明涉及一种用活性物质浸渍无孔聚合物药物载体的分批方法，其特征在于所述方法包括以下连续步骤：a）将活性物质与无孔聚合物药物载体混合，所述药物载体为 固体形式，不溶于超临界CO2，不是非交联聚乙烯吡咯烷酮; b）在没有水的情况下，以静态模式无搅拌地将步骤a）中获得的混合物与压力为80至170巴的超临界CO 2在31至90℃的温度下接触进行分子扩散步骤 C 1〜6小时; c）回收浸渍有步骤b）中获得的活性物质的聚合物药物载体，所述浸渍的药物载体是无孔的并且是固体形式，并且所述活性物质是无定形形式，所述方法在没有额外的 溶剂。 本发明还涉及一种浸渍有活性物质的无孔固体形式的聚合物药物载体，其特征在于所述载体可通过本发明的方法获得，其中活性物质为无定形形式， 并且聚合物药物载体不是非交联的聚乙烯吡咯烷酮并且不溶于超临界CO 2。

    COMBINATION OF A C-MET ANTAGONIST AND AN AMINOHETEROARYL COMPOUND FOR THE TREATMENT OF CANCER
    3.
    发明申请
    COMBINATION OF A C-MET ANTAGONIST AND AN AMINOHETEROARYL COMPOUND FOR THE TREATMENT OF CANCER 审中-公开
    C-MET拮抗剂和用于治疗癌症的氨基胆碱化合物的组合

    公开(公告)号：WO2010003992A8

    公开(公告)日：2011-02-10

    申请号：PCT/EP2009058709

    申请日：2009-07-08

    Applicant: PF MEDICAMENT ,  GOETSCH LILIANE

    Inventor： GOETSCH LILIANE

    IPC: A61K39/395 ,  A61K31/435 ,  A61P35/00

    CPC classification number: A61K31/4545 ,  A61K31/435 ,  A61K39/3955 ,  A61K39/39558 ,  C07K16/2863 ,  C07K2317/73 ,  C07K2317/76 ,  A61K2300/00

    Abstract: The invention also relates to a composition comprising an antibody antagonist to c-Met and an aminoheteroaryl compound, particularly as a medicament. The present invention also comprises a pharmaceutical composition comprising said anti c-Met antibody and said aminoheteroaryl compound as combination products for simultaneous, separate or sequential use. The invention relates to the use of the composition of the invention for the treatment of cancer in a mammal.

    Abstract translation: 本发明还涉及包含c-Met的抗体拮抗剂和氨基杂芳基化合物，特别是作为药物的组合物。 本发明还包含一种药物组合物，其包含所述抗c-Met抗体和所述氨基杂芳基化合物作为用于同时，分开或顺序使用的组合产物。 本发明涉及本发明的组合物在哺乳动物中治疗癌症的用途。

    USE OF AN ANTI-CD151 ANTIBODY IN THE TREATMENT OF CANCER
    5.
    发明申请
    USE OF AN ANTI-CD151 ANTIBODY IN THE TREATMENT OF CANCER 审中-公开
    使用抗CD151抗体治疗癌症

    公开(公告)号：WO2008049990A2

    公开(公告)日：2008-05-02

    申请号：PCT/FR2007001688

    申请日：2007-10-15

    Applicant: PF MEDICAMENT ,  HAEUW JEAN-FRANCOIS ,  GOETSCH LILIANE

    Inventor： HAEUW JEAN-FRANCOIS ,  GOETSCH LILIANE

    IPC: A61K39/395 ,  A61P35/00 ,  A61P35/04 ,  C07K16/30

    CPC classification number: C07K16/2896 ,  A61K2039/505 ,  C07K2317/34

    Abstract: The present invention relates to the use of at least one antibody, or a functional fragment thereof, capable of binding to the CD151 protein and thus of inhibiting tumour growth, for the preparation of a medicament for use in the treatment of cancer. The invention also relates to a composition for the treatment of cancer, comprising, as active ingredient, at least one anti-CD151 antibody, or a functional fragment thereof, capable of binding to the CD151 protein and/or of inhibiting the development of primary tumours and/or of inhibiting its metastasis-promoting activity, wherein said antibodies may consist of the TS151 and/or TS151r antibodies.

    Abstract translation: 本发明涉及能够结合CD151蛋白并因此抑制肿瘤生长的至少一种抗体或其功能片段用于制备用于治疗癌症的药物的用途。 本发明还涉及用于治疗癌症的组合物，其包含能够结合CD151蛋白和/或抑制原发性肿瘤发展的至少一种抗CD151抗体或其功能片段作为活性成分 和/或抑制其转移促进活性，其中所述抗体可由TS151和/或TS151r抗体组成。

    1,2,4-TRIAZINE DERIVATIVES, PREPARATION AND USE THEREOF IN HUMAN THERAPY
    6.
    发明申请
    1,2,4-TRIAZINE DERIVATIVES, PREPARATION AND USE THEREOF IN HUMAN THERAPY 审中-公开
    1,2,4-三唑衍生物，其制备及其在人类治疗中的应用

    公开(公告)号：WO2006092507A8

    公开(公告)日：2007-11-01

    申请号：PCT/FR2006000469

    申请日：2006-03-02

    Applicant: PF MEDICAMENT ,  DUPONT-PASSELAIGUE ELISABETH ,  LEROY ISABELLE ,  PATOISEAU JEAN-FRANCOIS ,  JUNQUERO DIDIER ,  RIVAL YVES ,  DELHON ANDRE

    Inventor： DUPONT-PASSELAIGUE ELISABETH ,  LEROY ISABELLE ,  PATOISEAU JEAN-FRANCOIS ,  JUNQUERO DIDIER ,  RIVAL YVES ,  DELHON ANDRE

    IPC: C07D253/06 ,  A61K31/66 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61P17/00

    CPC classification number: C07D253/075

    Abstract: The invention concerns 3,5-dioxo-(2H,4H)-1,2,4-triazine derivatives of general formula (I), wherein: R 1 and R 2 , identical or different, represent a branched or linear C 1 -C 7 alkyl or alkenyl radical, a C 1 -C 6 alkyl radical substituted by groups such as trifluoromethyl, C 5 -C 6 cycloalkyl, nitrile, C 1 -C 4 alkoxycarbonylvinyl, hydroxycarbonylvinyl, C 1 -C 4 alkoxycarbonyl, carboxylate, benzyloxy or phenyl (for which the phenyl ring is optionally substituted by one or more groups such as C 1 -C 4 alkoyl, C 1 -C 4 alkoxy, nitro, halogen, trifluoromethyl); YR 3 represents oxygen or NR 3 for which R3 represents hydrogen, a linear or branched C 1 -C 7 alkyl or alkenyl radical, a C 1 -C 6 alkyl radical substituted by groups such as trifluoromethyl or phenyl (for which the phenyl ring is optionally substituted by one or more groups such as C 1 -C 4 alkoyl, C 1 -C 4 alkoxy, nitro, halogen, trifluoromethyl); Z represents an oxygen atom or a carbon atom capable of being bound to the ortho, meta or para positions of the phenyl group of formula I; n can be 0 to 5 when Z=C or 2 to 4 when Z=O; X represents oxygen or sulphur; R 4 , R 5 , R 6 , R 7 and R 8 represent hydrogen or fluorine; R 9 , R 10 and R 11 represent hydrogen or a linear or branched C 1 -C 5 alkyl group as well as the pharmaceutically acceptable base addition salts, and the various enantiomers of compounds having asymmetric carbons, and their mixtures in all proportions including in particular the racemic mixtures.

    Abstract translation: 本发明涉及通式（I）的3,5-二氧代 - （2H，4H）-1,2,4-三嗪衍生物，其中：R 1和R 2 ，相同或不同，表示支链或直链C 1 -C 7烷基或烯基，C 1 -C 3 - 被三氟甲基，C 5 -C 6环烷基，腈，C 1 -C 6亚烷基，C 1 -C 6亚烷基， 烷氧基羰基乙烯基，羟基羰基乙烯基，C 1 -C 4烷氧基羰基，羧酸酯，苄氧基或苯基（其中苯环任选被一个或多个基团取代 例如C 1 -C 4烷酰基，C 1 -C 4烷氧基，硝基，卤素，三氟甲基），C 1 -C 4烷基，C 1 -C 4烷氧基， ; YR 3表示氧或NR 3，其中R 3表示氢，直链或支链C 1 -C 7 - 烷基或烯基，被诸如三氟甲基或苯基的基团取代的C 1 -C 6 -C 6烷基（其中苯环任选被一个或多个基团取代 作为C 1 -C 4烷酰基，C 1 -C 4烷氧基，硝基，卤素，三氟甲基）; C 1 -C 4烷基，C 1 -C 4烷氧基，硝基，卤素，三氟甲基。 Z表示可与式I的苯基的邻位，间位或对位结合的氧原子或碳原子; 当Z = C时，n可以为0〜5，Z = 0时为0〜4; X表示氧或硫; R 4，R 5，R 6，R 7和R 8表示 氢或氟; R 9，R 10和R 11表示氢或直链或支链C 1 -C 1 - 5个烷基以及药学上可接受的碱加成盐，以及具有不对称碳的化合物的各种对映异构体及其各种比例的混合物，特别包括外消旋混合物。

Patent Agency Ranking